DJIA 17,071.22 -41.93 -0.25%
NASDAQ 4,505.85 -6.34 -0.14%
S&P 500 1,977.80 -5.05 -0.25%
market minute promo

Gilead Sciences (NASDAQ: GILD)

107.51 -0.87 (-0.80%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

GILD $107.51 -0.80%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $107.59
Previous Close $108.38
Daily Range $106.45 - $108.68
52-Week Range $58.81 - $110.64
Market Cap $162.5B
P/E Ratio 24.41
Dividend (Yield) $0.00 (0.0%)
Volume 8,060,948
Average Daily Volume 15,340,983
Current FY EPS $7.26





Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website:

News & Commentary

Gilead Sciences, Inc. Takes Aim at Bristol-Myers Squibb

Gilead Sciences has filed for approval of its next generation hepatitis C drug in Japan in a move that will challenge Bristol-Myers first to market advantage.

Bristol-Myers' Opdivo Under Review in US, EU for Cancer Treatment - Analyst Blog

Alimera/pSivida's Iluvien Receives FDA Approval for DME - Analyst Blog

Gilead Sciences, Inc. Consolidating Gains?

AMGN, ACT And GILD, Pushing Drugs Industry Downward

Pharma Stocks: Surprising Shift In U.S. Drug Market

Update: European Positive Opinion About Gilead's Harvoni Supports Our Bull Case

What This Huge George Soros Mistake Can Teach You

George Soros is an investing genius. Still, he does make the occasional mistake. Here is a look at recent mistake with Gilead Sciences Inc. that cost the billionaire serious gains.

Agios Pharmaceuticals Inc, Altria Group Inc Highlight CNBC's Stock Pops & Drops From September 26

Celldex (CLDX) Up on Pilot Study Initiation on CDX-301 - Analyst Blog

Celldex (CLDX) Up on Pilot Study Initiation on CDX-301 - Analyst Blog

See More GILD News...

GILD's Top Competitors

GILD $107.51 (-0.80%)
Current stock: GILD
AMGN $140.07 (-0.70%)
Current stock: AMGN
CELG $95.64 (1.25%)
Current stock: CELG
$0.00 (0.00%)
Current stock: